Craftport Cannabis Résultats passés
Passé contrôle des critères 0/6
Craftport Cannabis's earnings have been declining at an average annual rate of -18.4%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 49.5% per year.
Informations clés
-18.4%
Taux de croissance des bénéfices
8.8%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 23.1% |
| Taux de croissance des recettes | 49.5% |
| Rendement des fonds propres | n/a |
| Marge nette | -4,454.1% |
| Dernière mise à jour des bénéfices | 30 Sep 2022 |
Mises à jour récentes des performances passées
Ventilation des recettes et des dépenses
Comment Craftport Cannabis gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -8 | 3 | 0 |
| 30 Jun 22 | 0 | -8 | 3 | 0 |
| 31 Mar 22 | 1 | -10 | 3 | 0 |
| 31 Dec 21 | 1 | -10 | 3 | 0 |
| 30 Sep 21 | 1 | -13 | 3 | 0 |
| 30 Jun 21 | 1 | -12 | 3 | 0 |
| 31 Mar 21 | 1 | -10 | 3 | 0 |
| 31 Dec 20 | 1 | -10 | 3 | 0 |
| 30 Sep 20 | 1 | -1 | 4 | 0 |
| 30 Jun 20 | 0 | -3 | 4 | 0 |
| 31 Mar 20 | 0 | -3 | 5 | 0 |
| 31 Dec 19 | 0 | -4 | 5 | 0 |
| 30 Sep 19 | 0 | -6 | 6 | 0 |
| 30 Jun 19 | 0 | -6 | 6 | 0 |
| 31 Mar 19 | 0 | -6 | 6 | 0 |
| 31 Dec 18 | 0 | -6 | 6 | 0 |
| 30 Sep 18 | 0 | -8 | 5 | 0 |
| 30 Jun 18 | 0 | -7 | 4 | 0 |
| 31 Mar 18 | 0 | -5 | 3 | 0 |
| 31 Dec 17 | 0 | -4 | 2 | 0 |
| 30 Sep 17 | 0 | -2 | 1 | 0 |
| 30 Jun 17 | 0 | -1 | 1 | 0 |
| 31 Mar 17 | 0 | -1 | 1 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
Des revenus de qualité: CFT is currently unprofitable.
Augmentation de la marge bénéficiaire: CFT is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: CFT is unprofitable, and losses have increased over the past 5 years at a rate of 18.4% per year.
Accélération de la croissance: Unable to compare CFT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: CFT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).
Rendement des fonds propres
ROE élevé: CFT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.